Chimeric antigen receptor T-cell therapy has exhibited “compelling” efficacy and safety in lupus, allowing 84% of patients to ...

Get key insights from Bristol-Myers Squibb's Q3 2025 earnings call—growth highlights, raised guidance, and strategic pipeline updates.

Edwards Lifesciences reports strong Q3 2025 earnings, raises guidance, and highlights growth in heart therapies.

The NHS 10 Year Health Plan calls for a strategic shift to support people to live longer healthier and more independent lives ...

Nonfactor therapies may reduce costs associated with bleeding-related hospitalizations and use of bypassing agents. One study ...

Q3 2025 Earnings Call Transcript October 29, 2025 AtriCure, Inc. beats earnings expectations. Reported EPS is $-0.01, ...

The authors find that LLM-based chatbots often fail to identify critical warning signs such as suicidal ideation, depression ...

Q3 2025 Earnings Call Transcript October 30, 2025 Operator: Good afternoon. Thank you for attending the Guardant Health Q3 ...

Med Population Health, Inc., the leading platform for employer-sponsored preemptive health management, today announced a new ...

Completed rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC On track to report topline pivotal data for neladalkib in TKI pre-treated ...

A top heart transplant hospital was found in a confidential review to have denied transplants to suitable patients and ...